DEXCOM INC (1DXCM.MI) Stock Price & Overview

BIT:1DXCMUS2521311074

Current stock price

62.77 EUR
+1.58 (+2.58%)
Last:

The current stock price of 1DXCM.MI is 62.77 EUR. Today 1DXCM.MI is up by 2.58%.

1DXCM.MI Key Statistics

Market Cap
24.158B
P/E
34.68
Fwd P/E
28.71
EPS (TTM)
1.81
Dividend Yield
N/A

1DXCM.MI Stock Performance

Today
+2.58%
1 Week
+2.67%
1 Month
N/A
3 Months
N/A
Longer-term
6 Months N/A
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

1DXCM.MI Stock Chart

DEXCOM INC / 1DXCM Daily stock chart

1DXCM.MI Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to 1DXCM.MI.


Chartmill TA Rating
Chartmill Setup Rating

1DXCM.MI Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to 1DXCM.MI. 1DXCM.MI gets an excellent profitability rating and is at the same time showing great financial health properties.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

1DXCM.MI Earnings

On February 12, 2026 1DXCM.MI reported an EPS of 0.45 and a revenue of 1.26B. The company missed EPS expectations (-32.12% surprise) and missed revenue expectations (-0.9% surprise).

Next Earnings DateApr 29, 2026
Last Earnings DateFeb 12, 2026
PeriodQ4 / 2025
EPS Reported$0.45
Revenue Reported1.26B
EPS Surprise -32.12%
Revenue Surprise -0.90%

1DXCM.MI Forecast & Estimates

37 analysts have analysed 1DXCM.MI and the average price target is 74.94 EUR. This implies a price increase of 19.39% is expected in the next year compared to the current price of 62.77.

For the next year, analysts expect an EPS growth of 20.81% and a revenue growth 12.81% for 1DXCM.MI


Analysts
Analysts84.32
Price Target74.94 (19.39%)
EPS Next Y20.81%
Revenue Next Year12.81%

1DXCM.MI Groups

Sector & Classification

Index Membership

1DXCM.MI Financial Highlights

Over the last trailing twelve months 1DXCM.MI reported a non-GAAP Earnings per Share(EPS) of 1.81. The EPS increased by 26.67% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)720.70M
Industry RankSector Rank
PM (TTM) 15.96%
ROA 9.61%
ROE 26.44%
Debt/Equity 0.47
Chartmill High Growth Momentum
EPS Q2Q%51.11%
Sales Q2Q%13.12%
EPS 1Y (TTM)26.67%
Revenue 1Y (TTM)N/A

1DXCM.MI Ownership

Ownership
Inst Owners100.29%
Shares384.86M
Float380.42M
Ins Owners0.2%
Short Float %N/A
Short RatioN/A

About 1DXCM.MI

Company Profile

1DXCM logo image DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. The company is headquartered in San Diego, California and currently employs 11,000 full-time employees. The company went IPO on 2005-04-14. The firm is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The firm enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.

Company Info

IPO: 2005-04-14

DEXCOM INC

6340 Sequence Drive

San Diego CALIFORNIA US

Employees: 11000

1DXCM Company Website

1DXCM Investor Relations

Phone: 13026365400

DEXCOM INC / 1DXCM.MI FAQ

Can you describe the business of DEXCOM INC?

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. The company is headquartered in San Diego, California and currently employs 11,000 full-time employees. The company went IPO on 2005-04-14. The firm is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The firm enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.


Can you provide the latest stock price for DEXCOM INC?

The current stock price of 1DXCM.MI is 62.77 EUR. The price increased by 2.58% in the last trading session.


Does 1DXCM stock pay dividends?

1DXCM.MI does not pay a dividend.


What is the ChartMill technical and fundamental rating of 1DXCM stock?

1DXCM.MI has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


How is the valuation of DEXCOM INC (1DXCM.MI) based on its PE ratio?

The PE ratio for DEXCOM INC (1DXCM.MI) is 34.68. This is based on the reported non-GAAP earnings per share of 1.81 and the current share price of 62.77 EUR.


What is the employee count for 1DXCM stock?

DEXCOM INC (1DXCM.MI) currently has 11000 employees.


Who owns DEXCOM INC?

You can find the ownership structure of DEXCOM INC (1DXCM.MI) on the Ownership tab.